Shares of Glenmark Prescription drugs Ltd soared 3% on 3 March after the corporate introduced buying and launching Acetylcysteine injection in the US by its subsidiary.
Glenmark is ready to introduce its new Acetylcysteine Injection within the U.S. market in a 6 gm/30 mL (200 mg/mL) energy, accessible in single-dose vials, additional increasing its injectable product portfolio.
This newly launched injection is designed to offer the identical therapeutic advantages as Acetadote Injection (6 gm/30 mL, 200 mg/mL), a branded drug manufactured by Cumberland Prescription drugs Inc., Glenmark knowledgeable the inventory exchanges.
Acetylcysteine is extensively used for treating acetaminophen overdose and as a mucolytic agent to handle respiratory circumstances.
The U.S. Meals and Drug Administration (FDA) authorized Glenmark’s model primarily based on the established security and efficacy knowledge of Acetadote Injection.
Glenmark acquired the Abbreviated New Drug Software (ANDA) for this Acetylcysteine Injection from Aspen Pharma USA Inc., aiming to supply a cheap and dependable various available in the market.
In line with IQVIA gross sales knowledge for the 12 months ending January 2025, Acetadote Injection recorded annual gross sales of roughly $15.2 million within the U.S. market.
At 3:30 pm, the shares of Glenmark Pharma have been buying and selling 3.00% larger at 1,317.35 on NSE.
Ask the analyst & get immediate reply about Glenmark Prescription drugs Ltd.
Unlock worthwhile alternatives day-after-day! Unicorn Indicators gives actionable intraday buying and selling alerts for shares and futures. Don’t miss out – obtain Unicorn Indicators and begin profitable now!
